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OBJECTIVE: A new diabetes risk score (DRS) can accurately
and precisely predict development of type 2 diabetes (T2D)and
may improve patient outcome if routinely used as part of popu-
lation screening for at risk patients. The DRS uses algorithms
with panels of 5–9 serum biomarkers detected by an ultrasensi-
tive molecular counting technology. We sought to evaluate the
cost-effectiveness of DRS. METHODS: Using data from a ﬁve-
year prospective validation study, we developed a ten year cost-
effectiveness model of DRS. Dependent upon the subjects score,
we modeled testing and treatment patterns, costs and outcomes
of the fraction of the population who converted to T2D, those
that did not convert and those that died. All comparisons were
made to a no-testing strategy. Cost inputs including hypothetical
reimbursement for the test, preventive treatment, costs of disease
for T2D, preference weights and mortality were obtained from
the literature. A United States health care system perspective was
taken. Univariate sensitivity analyses and scenario analyses were
performed. RESULTS: We simulated a cohort of patients over
age 40 with a BMI of 25 or greater. We assumed 12.5% of tested
patients would develop T2D with no intervention over ﬁve years.
Annual mortality for T2D is 1.08%. Base case simulation
showed that the DRS is cost effective at ﬁve years ($9000/QALY)
and at ten years ($400/QALY) compared to a no-testing strat-
egy. Sensitivity analyses suggest that the incremental cost-
effectiveness ratio is most sensitive to the cost and effectiveness of
preventive treatment and the pre-test risk of converting to T2D.
Using DRS to identify patients at high risk was cost effective up
to a reimbursement level of $1100 per test. CONCLUSION:
Under a variety of scenarios, early prediction of type 2 diabetes
with a serum biomarker panel is cost-effective given certain
assumptions regarding screening efﬁciency and availability and
effectiveness of preventive treatment.
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OBJECTIVE: This study examined the association between
medication adherence and health care costs and utilization in
diabetes patients. Previous studies that have investigated this
relationship, did not necessarily examine patients newly starting
antidiabetic therapy. METHODS: The North Carolina Medicaid
database was used to identify type 2 diabetes patients 18–64
years using at least one ICD-9 code for type 2 diabetes (250.xx,
excluding type 1 diabetes codes) and one NDC code (National
Drug Code) for antidiabetic medication. New starts of met-
formin, sulfonylureas, and thiazolidinediones, the most com-
monly used oral antidiabetic medications, were identiﬁed during
July 1, 2001 to June 30, 2002. Adherence was measured as
Medication Possession Ratio (MPR). Total annual health care
costs, all-cause hospitalization and all-cause emergency depart-
ment (ED) visit were examined. Linear multiple regression analy-
sis was employed to study the effect on health care costs and
logistic regression analyses for hospitalization and ED visit.
RESULTS: Adherence to new oral antidiabetic medication was
56%. Mean total annual health care costs were $10,000. Almost
37% were hospitalized and 40% had ED visit. No association
was found between medication adherence and costs. Increasing
MPR by 10% was signiﬁcantly associated with 6.9% decrease in
likelihood of hospitalization (OR: 0.31, 95%CI: 0.23–0.41) and
5.1% decrease in likelihood of ED visit (OR: 0.49, 95% CI:
0.38–0.63). CONCLUSION: Increased medication adherence to
newly started oral antidiabetic therapies was associated with
decreased risk of health care utilization in Mediciaid-enrolled
patients with type 2 diabetes. Physicians and pharmacists’
active role in advising Medicaid patients on importance of phar-
macotherapy, especially, for those newly starting a therapy is
necessary.
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OBJECTIVE: To evaluate the prevalence of noncompliance with
American Diabetes Association (ADA) guidelines for prevention
and management of diabetes complications and its association
with diabetes-related burden. METHODS: California Medicaid
administrative data from 2002 through 2004 were used to iden-
tify patients ¡Ý40 years of age with a diagnosis of type 2 diabetes
mellitus (T2DM) or a prescription for one anti-diabetic medica-
tion. Patients who did not have two glycosylated hemoglobin
(HbA1c) tests, one eye exam, and one low-density lipoprotein-
cholesterol (LDL-C) test at year 2004 were identiﬁed as noncom-
pliant with ADA guidelines. Disease burden was deﬁned as any
inpatient or emergency room visit. Logistic regressions were used
to identify factors associated with disease burden in 2004.
RESULTS: Of 29,307 individuals who were identiﬁed as T2DM,
12,293 (42%) were noncompliant with ADA guidelines, 26,649
(91%) did not have two HbA1c tests, 13,315 (45%) did not have
an eye examination, and 23,765 (81%) did not have an LDL-C
test. Of the 22,699 (77%) patients who ﬁlled at least an anti-
diabetic medication, only 14,659 (65%) were persistent with the
medication (proportion days covered 0.8). A total of 6689
(23%) patients had disease burden, and 868 (3%) had diabetes-
related disease burden. When compared with patients who com-
plied with ADA guidelines, noncompliers were more like to have
disease burden (OR = 1.5, 95% CI = 1.4–1.6) or diabetes-related
disease burden (OR = 1.9, CI = 1.6–2.3). Other factors signiﬁ-
cantly associated with diabetes-related disease burden included
male gender (OR = 1.2, CI = 1.1–1.4), race other than White and
Black (OR = 1.3, CI = 1.1–1.5), no Medicare eligibility
(OR = 2.1, CI = 1.7–2.5), comorbidity (OR = 1.6, CI = 1.6–1.7),
and nonpersistence with anti-diabetic medication (OR = 1.4,
CI = 1.2–1.7). CONCLUSION: Appropriate diabetes care can
prevent diabetes complications and avoid increased medical cost.
These California Medicaid data suggest the need to develop and
evaluate intervention programs targeted at T2DM patients who
are at risk for noncompliance with diabetes care, especially those
with comorbidities and/or those nonpersistent with anti-diabetic
medication.
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